OptiNose Inc (NASDAQ:OPTN) has been assigned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.
Brokerages have set a 12-month consensus price target of $29.67 for the company and are predicting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also given OptiNose an industry rank of 169 out of 265 based on the ratings given to related companies.
Several analysts have recently commented on OPTN shares. BMO Capital Markets started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They set an “outperform” rating and a $29.00 price target on the stock. Jefferies Group started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They set a “buy” rating and a $27.00 price target on the stock. Piper Jaffray Companies started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They set an “overweight” rating and a $27.00 price target on the stock. Finally, Royal Bank of Canada started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price target on the stock.
COPYRIGHT VIOLATION WARNING: “OptiNose Inc (OPTN) Given $29.67 Average Target Price by Analysts” was first reported by BBNS and is owned by of BBNS. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/optinose-inc-optn-given-29-67-average-target-price-by-analysts/1822836.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with our FREE daily email newsletter.